about
Evaluation of Models of Parkinson's DiseaseMitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's DiseasesHemispheric differences in the mesostriatal dopaminergic systemSex differences in Parkinson's diseaseLow concentrations of methamphetamine can protect dopaminergic cells against a larger oxidative stress injury: mechanistic studyParkin promotes degradation of the mitochondrial pro-apoptotic ARTS proteinA current review of cypermethrin-induced neurotoxicity and nigrostriatal dopaminergic neurodegenerationEstrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine.Neuroprotective Properties of a Standardized Extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertão), as Evaluated by a Parkinson's Disease Model in RatsAlterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicityPathophysiology of parkinsonism.Impaired voluntary wheel running behavior in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.Cortex Fraxini (Qingpi) Protects Rat Pheochromocytoma Cells against 6-Hydroxydopamine-Induced ApoptosisCombination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.Exposure to Early Life Stress Results in Epigenetic Changes in Neurotrophic Factor Gene Expression in a Parkinsonian Rat Model.The Enemy within: Innate Surveillance-Mediated Cell Death, the Common Mechanism of Neurodegenerative Disease.The role of exercise in facilitating basal ganglia function in Parkinson's diseaseA single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats.Antioxidants in central nervous system diseases: preclinical promise and translational challenges.Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.Role of movement in long-term basal ganglia changes: implications for abnormal motor responses.Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease.Glutamate receptors as therapeutic targets for Parkinson's disease.The SH-SY5Y cell line in Parkinson's disease research: a systematic review.Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis.Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases.Neurogenesis in Neurotoxin-induced Animal Models for Parkinson's Disease-A Review of the Current Status.A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Harnessing neurogenesis for the possible treatment of Parkinson's disease.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.Advances in non-dopaminergic treatments for Parkinson's diseasePost 6-OHDA lesion exposure to stress affects neurotrophic factor expression and aggravates motor impairment.Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway.Mitochondrial control of cell bioenergetics in Parkinson's disease.
P2860
Q26772843-1565795B-A709-4F27-948E-FBF8D3847A8AQ26859141-C347893C-2DC7-49A1-A572-00CFB84EC269Q26862775-8C5242E1-A3D4-4EAA-8F54-DD79121329C0Q27025107-877BF02F-5354-4F87-8C13-E30D6B49D013Q28477457-8C95F828-C2DC-4B8D-BECB-270D18206370Q28727358-220803B1-1126-4D03-A57A-4A973AEEC483Q30464056-24F7C17D-7373-4E72-B9F8-77F2C04C0C34Q30478476-5087A7AE-8CCE-4FD3-954F-F2A73502D010Q30489404-FD69BBBD-937F-4C06-B5FE-64875EF069A6Q33873281-5013F3CE-1CE2-446C-93E8-91BFB08913B7Q33905707-51DA3753-8148-43F1-A427-6A751C094494Q34211654-59AD1A72-BE35-4FF8-A69A-E963E1FC0BC5Q34777496-BA412A4F-0BFB-4BD2-878E-D808CB2BF775Q35133598-B534E2AB-1E1F-4C56-B182-A625C684637FQ35492255-99C1ADAA-9D7B-4DA8-91CC-260C8488BAE1Q35922870-EF7F570C-A2F9-478C-B78A-BA6A02F685A4Q35971342-3C941D98-5EB3-4386-948E-BCBF4075097AQ35989000-070802D4-C42C-4B50-BC00-40B8489B28ACQ36254618-0E03B87F-70AF-4315-B507-8A41A9585CE1Q36528892-5D7E8CE3-5383-4FA1-A8F5-D2EDF2A6563BQ36887309-3722EC15-15B8-40E9-BA4D-BD87582FBF10Q36951038-E635E6C2-B96A-4630-9C2A-B729C6342FAFQ37080923-40AC3CCA-CEC1-4BE4-9C98-CBC784C2AC53Q37159979-192E335E-6A55-4EAB-A8C5-F2892D85B1FAQ37210678-FA20043D-BC57-43C0-8456-CCA8C49F9F37Q37249385-CA604BFF-6B7F-4FF5-903C-D3F7F106BE2FQ37509323-0327EBD3-98F5-4EAE-826E-15905B62349CQ37585401-E0A49D22-38DA-4CF4-8F05-965591B50590Q37602366-1A0B5EAB-9CC3-44E2-BFAE-F7E39ECF7306Q37727186-11F49FD7-3E27-40C3-BDFF-1F978278AC84Q37798463-70DBE109-893F-4739-B7B0-7E5215A59AA0Q37978305-DCC9E84E-8B2E-4635-9483-050F45A332B1Q38111109-14625E11-B11E-49EC-8E17-65A5320DE834Q38169996-F8C8C656-A06F-438E-9459-B23762648CFCQ38203839-5A974314-DAA5-4863-98FF-A9F93CDB9E0AQ38207680-A8AE465B-2A56-41EF-A67B-D255D9A37242Q38218083-E0D317B8-F498-4A97-84A6-C75D57DC1FCAQ38711427-6DAE8B2D-A2B7-4CB3-9966-6C654331ED5CQ38714411-B73B14A5-B33F-44B6-8F93-4F9D1D438119Q38811534-B150BF1B-C09D-490C-8173-CD74B77009F7
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The 6-hydroxydopamine model of Parkinson's disease.
@en
type
label
The 6-hydroxydopamine model of Parkinson's disease.
@en
prefLabel
The 6-hydroxydopamine model of Parkinson's disease.
@en
P2860
P356
P1476
The 6-hydroxydopamine model of Parkinson's disease.
@en
P2093
Anna R Carta
P2860
P2888
P304
P356
10.1007/BF03033565
P577
2007-04-01T00:00:00Z